tbuckley/cabot-search huggingface dataset:
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Authors: Man-Fung Yuen, Stephen Locarnini, Tien Huey Lim, Simone I. Strasser, William Sievert, Wendy Cheng, Alex J. Thompson, Bruce D. Given, Thomas Schluep, James Hamilton, Michael Biermer, Ronald Kalmeijer, Maria Beumont, Oliver Lenz, Filip De Ridder, Gavin Cloherty, Danny Ka-Ho Wong, Christian Schwabe, Kathy Jackson, Ching Lung Lai, Robert G. Gish, Edward Gane
Journal: Journal of Hepatology (2022)

RNA interference therapy has been shown to reduce hepatitis B surface antigen (HBsAg) levels in preclinical models, which could confer functional cure in patients with chronic hepatitis B. This phase IIa trial (ClinicalTrials.gov Identifier: NCT03365947) assessed the safety and efficacy of the small-interfering RNA JNJ-73763989 (JNJ-3989) plus a nucleos(t)ide analogue (NA), with/without the capsid assembly modulator JNJ-56136379 (JNJ-6379) in patients with chronic hepatitis B.Treatment-naïve and NA-suppressed patients received 3 subcutaneous JNJ-3989 doses every week (QW; 100, 200, or 300 mg), 2 weeks (Q2W; 100 mg) or 4 weeks (Q4W; 25, 50, 100, 200, 300, or 400 mg), or JNJ-3989 Q4W (200 mg) plus oral JNJ-6379 250 mg daily for 12 weeks. Patients received NAs throughout.Eighty-four patients were recruited. All treatments were well tolerated, with all 5 serious adverse events considered unrelated to study drugs. JNJ-3989 100 to 400 mg Q4W resulted in HBsAg reductions ≥1 log10 IU/ml from baseline in 39/40 (97.5%) patients at the nadir. All patients receiving the triple combination (n = 12) had HBsAg reductions ≥1 log10 IU/ml from baseline at the nadir. HBsAg reductions were similar for HBeAg-positive (n = 21) and HBeAg-negative (n = 47) patients in all JNJ-3989 Q4W treatment arms, including the triple combination (n = 68). Smaller HBsAg reductions were seen with 25 mg (n = 8) and 50 mg (n = 8) than with 100 to 400 mg (n = 40). Shorter dosing intervals (QW [n = 12] and Q2W [n = 4]) did not improve response vs. Q4W dosing. HBsAg reductions ≥1 log10 IU/ml from baseline persisted in 38% of patients 336 days after the last JNJ-3989 dose.JNJ-3989 plus an NA, with/without JNJ-6379, was well tolerated and resulted in HBsAg reductions up to 336 days after the last JNJ-3989 Q4W dose.NCT03365947.Hepatitis B virus affects people's livers and produces particles called hepatitis B surface antigen (HBsAg) that damage a person's liver and can help the virus infect a person for a long time, known as chronic hepatitis B (CHB). In this study, a new treatment called JNJ-3989 was assessed (in combination with normal treatment known as nucleos(t)ide analogues), for its safety and effectiveness in reducing the number of HBsAg particles in people with CHB. The results of this study showed that treatment with JNJ-3989 could be safe for people with CHB, lowered their HBsAg levels, and kept HBsAg levels lowered for 336 days in 38% of patients after receiving their last dose of JNJ-3989.
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
Authors: Ansel Tang, Cheng Han Ng, Poh Hui Phang, Kai En Chan, Yip Han Chin, Clarissa Elysia Fu, Rebecca Wenling Zeng, Jieling Xiao, Darren Jun Hao Tan, Jingxuan Quek, Wen Hui Lim, Lung Yi Mak, Jiong-wei Wang, Nicholas W.S. Chew, Nicholas Syn, Daniel Q. Huang, Mohammad Shadab Siddiqui, Arun Sanyal, Mark Muthiah, Mazen Noureddin
Journal: Clinical Gastroenterology and Hepatology (2022)
Patient Preferences for Colorectal Cancer Screening Tests in Light of Lowering the Screening Age to 45 Years
Authors: Katherine E. Makaroff, Jaspreet Shergill, Marie Lauzon, Carine Khalil, Sangeeta C. Ahluwalia, Brennan M.R. Spiegel, Christopher V. Almario
Journal: Clinical Gastroenterology and Hepatology (2022)
Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation
Authors: Cameron Goff, Anjiya Shaikh, Karthik Goli, Hashem B. El-Serag, Fasiha Kanwal, George Cholankeril, Abbas Rana, Faud Z. Aloor, Rosann Cholankeril, Nicole E. Rich, Jihane N. Benhammou, Donghee Kim, Aijaz Ahmed, John Goss
Journal: Clinical Gastroenterology and Hepatology (2022)

The major risk factor for developing hepatocellular carcinoma (HCC) is chronic liver disease, with hepatitis C virus (HCV) and alcohol-related liver disease (ARLD) predominating historically in the United States.1 However, with the recent availability of safe and effective direct-acting antiviral (DAA) therapy for HCV, and the continuing rise in nonalcoholic steatohepatitis (NASH), the relative etiology of HCC could further evolve.1–4 In 2016, ARLD and NASH surpassed HCV as the leading indication for liver transplant (LT) in patients without HCC; similar trends may be expected for HCC LT downstream.
Sars-Cov-2 antigen tests predict infectivity based on viral culture: comparison of antigen, PCR viral load, and viral culture testing on a large sample cohort
Authors: James E. Kirby, Stefan Riedel, Sanjucta Dutta, Ramy Arnaout, Annie Cheng, Sarah Ditelberg, Donald J. Hamel, Charlotte A. Chang, Phyllis J. Kanki
Journal: Clinical Microbiology and Infection (2022)
Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial
Authors: Chun-Yan Lan, Jing Zhao, Fan Yang, Ying Xiong, Rong Li, Yu Huang, Jing Wang, Chang Liu, Xue-Han Bi, Hai-Hong Jin, Jin Meng, Wei-Hong Zhao, Li Zhang, Ya-Fei Wang, Min Zheng, Xin Huang
Journal: Cell Reports Medicine (2022)

This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The median duration of response (DOR) has not been reached, and 61.3% of patients have a DOR of at least 8 months. The median progression-free survival (PFS) is 7.8 months, and the median overall survival (OS) has not been reached. The PD-L1-positive group has an ORR of 25.0%, whereas the PD-L1-negative group has an ORR of 92.9%. Treatment-related grade 3 or 4 adverse events (AEs) occur in 70.6% of patients, with the most common being hypertension (29.4%) and palmar-plantar erythrodysesthesia syndrome (29.4%). Anlotinib plus TQB2450 show promising antitumor activity and manageable toxicities in patients with platinum-resistant or -refractory ovarian cancer. A phase 3 randomized controlled trial to further validate our findings is ongoing.
Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals
Authors: Gaud Catho, Julien Sauser, Valentina Coray, Serge Da Silva, Luigia Elzi, Stephan Harbarth, Laurent Kaiser, Christophe Marti, Rodolphe Meyer, Francesco Pagnamenta, Javier Portela, Virginie Prendki, Alice Ranzani, Nicolò Saverio Centemero, Jerome Stirnemann, Roberta Valotti, Nathalie Vernaz, Brigitte Waldispuehl Suter, Enos Bernasconi, Benedikt D Huttner
Journal: The Lancet Infectious Diseases (2022)
Type I collagen decorated nanoporous network on titanium implant surface promotes osseointegration through mediating immunomodulation, angiogenesis, and osteogenesis
Authors: Yuyu Zhao, Long Bai, Yi Zhang, Runhua Yao, Yonghua Sun, Ruiyue Hang, Xiangyang Chen, Huaiyu Wang, Xiaohong Yao, Yin Xiao, Ruiqiang Hang
Journal: Biomaterials (2022)
P35-8 BRCA mutation test for castration-resistant prostate cancer in Iwate prefecture, Japan
Authors: Shigekatsu Maekawa, Kenta Ishikawa, Fumiko Amano, Tomohiko Matsuura, Renpei Kato, Yoichiro Kato, Mitsugu Kanehira, Takata Ryo, Jun Sugimura, Takaya Abe, Wataru Obara
Journal: Annals of Oncology (2022)
P78-2 Automatic quantification analysis of amrubicin and amrubicinol using LC-MS/MS
Authors: Makoto Maeda, Daisuke Amenomiya, Reiko Ando Makihara, Naomi Sakiyama, Yoshinori Makino, Eishi Imoto, Daisuke Kawakami, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Mitsunobu Ishikawa, Yoshimasa Saito, Toru Akagi, Hironobu Hashimoto, Noboru Yamamoto, Yuichiro Ohe, Tetsuya Furukawa
Journal: Annals of Oncology (2022)
O11-1 Prognostic impacts of loss of skeletal muscle mass during neoadjuvant chemotherapy in older esophageal cancer patients
Authors: Tsuyoshi Harada, Tetsuya Tsuji, Jnnya Ueno, You Koishihara, Nobuko Konishi, Nanako Hijikata, Aiko Ishikawa, Daisuke Kotani, Kojima Takashi, Hisashi Fujiwara, Takeo Fujita
Journal: Annals of Oncology (2022)
P10-1 A case of cytokine release syndrome due to immune checkpoint inhibitor and molecular targeted drug to huge hepatoma
Authors: Seiichi Yoshikawa, Daiki Natsui, Syunsuke Nojiri, Takayuki Watanabe, Keisuke Morita, Masashi Takatsuna, Yuuji Kobayashi, Tsutomu Miura, Manabu Takeuchi
Journal: Annals of Oncology (2022)
MO10-2 Emerging molecular targets in AML: IDH1/2- and menin-related mutations (HM-SCREEN-JAPAN01)
Authors: Sunggi Chi, Satoshi Uchiyama, Makoto Yoshimitsu, Kenji Ishitsuka, Kaoru Yamamoto, Yukinori Nakamura, Takahashi Naoto, Takeshi Kondo, Kensuke Usuki, Takaaki Ono, Tsutomu Kobayashi, Junya Kuroda, Satoshi Iyama, Makoto Nakamura, Kensuke Kojima, Suguru Fukuhara, Koji Izutsu, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami
Journal: Annals of Oncology (2022)
P66-6 Efficacy of everolimus in HR+ HER2- metastatic breast cancer patients after progression on CDK4/6 inhibitors
Authors: Kenichi Watanabe, Sayuri Kuwahara, Hanae Tachikawa, Hideki Maeda, Mitsugu Yamamoto, Nobumoto Tomioka, Masato Takahashi
Journal: Annals of Oncology (2022)
Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming
Authors: Dayuan Wang, Xiao Gu, Xinyi Ma, Jun Chen, Qizhi Zhang, Zhihua Yu, Juan Li, Meng Hu, Xiaofang Tan, Yuyun Tang, Jianrong Xu, Minjun Xu, Qingxiang Song, Huahua Song, Gan Jiang, Zaiming Tang, Xiaoling Gao, Hongzhuan Chen
Journal: Acta Pharmaceutica Sinica B (2022)

Microglial surveillance plays an essential role in clearing misfolded proteins such as amyloid-beta, tau, and α-synuclein aggregates in neurodegenerative diseases. However, due to the complex structure and ambiguous pathogenic species of the misfolded proteins, a universal approach to remove the misfolded proteins remains unavailable. Here, we found that a polyphenol, α-mangostin, reprogrammed metabolism in the disease-associated microglia through shifting glycolysis to oxidative phosphorylation, which holistically rejuvenated microglial surveillance capacity to enhance microglial phagocytosis and autophagy-mediated degradation of multiple misfolded proteins. Nanoformulation of α-mangostin efficiently delivered α-mangostin to microglia, relieved the reactive status and rejuvenated the misfolded-proteins clearance capacity of microglia, which thus impressively relieved the neuropathological changes in both Alzheimer's disease and Parkinson's disease model mice. These findings provide direct evidences for the concept of rejuvenating microglial surveillance of multiple misfolded proteins through metabolic reprogramming, and demonstrate nanoformulated α-mangostin as a potential and universal therapy against neurodegenerative diseases.
MO8-4 Knowledge, attitudes and participants risk of lung cancer in Bangladeshi population: A nationwide cross-sectional study
Authors: Nur E. Alam, Md. Imam Hossain, Md. Shariful Islam, Siratul Kubra Shifat, Umme Suriea, Najmunnahar Muna, Rakibul Hasan, Ramisa Binti Mohiuddin, Md. Muzahidul Islam, Rahat Mollik, Shahin Mahmud, Md. Sanower Hossain, Kamal Chowdhury, A.K.M. Mohiuddin
Journal: Annals of Oncology (2022)
P10-6 Report of a case of sigmoid colon cancer simultaneously harboring the BRAF V600E mutation and NTRK3 fusion gene
Authors: Kirio Kawai, Masato Hayashi, Akira Hirota, Mariko Nishioka, Tomohiro Maesono, Naohiro Okano, Tomonori Mizutani, Fumio Nagashima, Tomohiko Taki, Junji Furuse
Journal: Annals of Oncology (2022)
MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study
Authors: Rui Kitadai, Tetsuhiko Asao, Takehito Shukuya, Gaku Yamamoto, Atsuto Mouri, Ryosuke Imai, Yoko Tsukita, Kazutoshi Isobe, Satoshi Watanabe, Mitsuhiro Kamimura, Ryo Morita, Keita Kudo, Minehiko Inomata, Kazunari Tateishi, Kazutaka Kakinuma, Hiroshige Yoshioka, Yukiko Namba, Taku Nakagawa, Kunihiko Kobayashi, Kazuhisa Takahashi
Journal: Annals of Oncology (2022)
P41-7 Two cases of BRAF mutant mCRC with intestinal stenosis responded to encorafenib + binimetinib + cetuximab: A case report
Authors: Ikuhiro Kita, Yoshihiro Okita, Kotone Hayuka, Hirofumi Suzuki, Akihiro Kondo, Akitsu Murakami, Eisuke Asano, Hiroyuki Okuyama, Takamasa Nishiuchi, Keiichi Okano, Akihito Tsuji
Journal: Annals of Oncology (2022)
O3-1 HM-SCREEN-Japan 01: a mutation profiling multicenter study on patients with acute myeloid leukemia
Authors: Naoko Hosono, Takahiro Yamauchi, Sunggi Chi, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Kensuke Usuki, Yoshikazu Utsu, Nobuyuki Aotsuka, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Yosuke Minami
Journal: Annals of Oncology (2022)
P74-6 Clinical course of colorectal cancer who experienced thromboembolism during treatment with anti-angiogenesis agents
Authors: Masashi Morimachi, Takeshi Kawakami, Ari Nishimura, Kunihiro Fushiki, Hiromichi Shirasu, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Journal: Annals of Oncology (2022)
O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158
Authors: Shunji Takahashi, Nobumasa Mizuno, Kosei Hasegawa, Koji Matsumoto, Shirong Han, Tsutomu Takatsuki, Fan Jin, Kazuhiko Nakagawa
Journal: Annals of Oncology (2022)
P68-10 A prospective study of the geriatric assessment in elderly stage III colorectal cancer patients on adjuvant chemotherapy
Authors: Tatsuya Okuno, Mitsuyoshi Tei, Yukihiro Yoshikawa, Masatoshi Nomura, Toshinori Sueda, Tae Matsumura, Hiromichi Miyagaki, Masanori Tsujie, Junichi Hasegawa, Yusuke Akamaru
Journal: Annals of Oncology (2022)
O18-3 Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC
Authors: Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, Akiyoshi Kanazawa, Yosuke Horita, Masahiro Goto, Naohiro Okano, Kaname Yamashita, Akihito Tsuji, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
Journal: Annals of Oncology (2022)
P7-1 Overall survival with the use of prophylactic cranial irradiation in limited stage-SCLC: A systematic review
Authors: Bhumika Raisinghani, Chelsie Angelius, Jocelyn N. Susanto, Richelle Ramli, Natasha K. Law, Mario Sutanto, Andree Kurniawan
Journal: Annals of Oncology (2022)
MO32-2 Mobile application targeting in cancer symptoms management
Authors: Phichai Chansriwong, Jitprapa Konmun, Suwannee Sirilerttrakul, Patamaporn Tangteerakoon, Sineenuch Ckumdee, Buasorn Wetchapan, Sasiphat Khudamkreng, Kedsarin Pinrarot, Aujchayaporn Rattanaphom, Teeraporn Klinumporn, Siraprapa Kritongsuk, Noppakan Wannakansophon, Yaowarat Chantraporn, Pinyo Utthiya, Noppadon Kongsuphon, Pimchanok Tuitemwong, Nintita Sripaiboonkij Thokanit
Journal: Annals of Oncology (2022)
MO32-4 Cost-effectiveness of SLOG vs mFOLFIRINOX as the first-line treatment in metastatic pancreatic ductal adenocarcinoma
Authors: Yi-Hsin Yang, Chen-Hao Wu, Nai-Jung Chiang, Yan-Shen Shan, Li-Yuan Bai, Chung-Pin Li, Jen-Shi Chen, Li-Tzong Chen
Journal: Annals of Oncology (2022)
P61-5 Examination of patients with advanced non-small cell lung cancer (NSCLC) responding to nivolumab monotherapy over 1 year
Authors: Saki Nakajima, Satoshi Watanabe, Takuhide Utsunomiya, Kiyokazu Yoshinoya, Hidehiro Honda, Suguru Yamamoto, Keita Kudo
Journal: Annals of Oncology (2022)
O4-4 Linguistic validation of a Japanese version of the Chemotherapy-induced Alopecia Distress Scale
Authors: Yosuke Aoyama, Yuichiro Kikawa, Akihiko Shimomura, Juhee Cho, Hitomi Sato, Kiyomi Nonogaki, Koichiro Yoshino, Taro Yamanaka, Rika Kizawa, Takeshi Yamaguchi, Michiko Kurikawa, Kiyo Tanaka, Yoko Kobayashi, Nobuko Tamura, Yuko Tanabe, Eri Hoshino, Kojiro Shimozuma, Koichi Suyama, Yuji Miura, Hidetaka Kawabata
Journal: Annals of Oncology (2022)
P14-4 A case of renal pelvic cancer treated with afatinib after reconsidering pathological diagnosis based on findings of CGP
Authors: Takumi Fujiwara, Yoshinaga Okugawa, Takahito Kitajima, Haruko Saiki, Yasutaka Tono, Hajime Fujimoto, Kanako Saito, Ryotaro Hashizume, Hiroshi Imai, Toshiro Mizuno, Tetsu Kobayashi
Journal: Annals of Oncology (2022)
MO38-6 A retrospective study on the success rate of microsatellite instability tests
Authors: Tatsuki Ikoma, Hiroshi Tato, Takanobu Shimada, Keitaro Doi, Takahito Ashihara, Takahumi Nonogaki, Hiroyuki Marusawa, Toshihide Shimada, Takehiko Tsumura
Journal: Annals of Oncology (2022)
P28-1 Improving survival in EGFR mutation-positive non-small cell lung cancer: Tokushukai REAl world Data project (TREAD 01)
Authors: Kiyoaki Uryu, Imamura Yosinori, Shimoyama Rai, Mase Takahiro, Fujimura Yoshiaki, Hayashi Maki, Ohtaki Megu, Otani Keiko, Shinozaki Nobuaki, Minami Hironobu
Journal: Annals of Oncology (2022)
MO36-4 Asian subgroup analysis in global POLAR program of calmangafodipir on top of mFOLFOX6 for the prevention of CIPN
Authors: Kei Muro, Kentaro Yamazaki, Keun-Wook Lee, Kensei Yamaguchi, Naotoshi Sugimoto, Sang-Cheul Oh, Taroh Satoh, Sung Yong Oh, Yoichiro Yoshida, Dae Young Zang, Ichiro Takemasa, Eiji Oki, Sang-Hee Cho, Jaw-Yuan Wang, Hiroshi Matsuoka, Anders Persson, Jacques Näsström, Yusuke Sonehara, Fumiko Nagahama, Takeshi Kato
Journal: Annals of Oncology (2022)
MO29-4 Sequential afatinib and osimertinib in Asians with EGFRm+ NSCLC: combined analysis of two non-interventional studies
Authors: Satoru Miura, Hyun Ae Jung, Shin Yup Lee, Seung Hyeun Lee, Min Ki Lee, Yong Chul Lee, Maximilian J. Hochmair, Cheng-Ta Yang, Angela Märten, James Chih-Hsin Yang, Sanjay Popat
Journal: Annals of Oncology (2022)
P76-1 Comparison of programmed death ligand-1 expression in NSCLC using 22C3 and SP142 antibodies in a single institute study
Authors: Satoru Miura, Tomosue Kajiwara, Junko Baba, Kenichi Koyama, Kimiko Azegami, Yuta Hosoda, Hiroaki Nishida, Akira Okada, Tadashi Aoki, Takashi Kawasaki, Hiroshi Tanaka
Journal: Annals of Oncology (2022)
P37-1 Liquid biopsy for the detection of the resistant mutation to ROS1 and RET inhibitors: A case series study
Authors: Yoshitaka Seki, Tatsuya Yoshida, Ken Masuda, Hidehito Horinouchi, Yuki Shinno, Yusukw Okuma, Yasushi Goto, Noboru Yamamoto, Kazuyoshi Kuwano, Kohno Takashi, Yuichiro Ohe
Journal: Annals of Oncology (2022)
P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan
Authors: Takashi Kijima, Koichi Azuma, Hidetoshi Hayashi, Koichi Nakatani, Tatsuro Fukuhara, Yukihiro Toi, Hisao Imai, Yasuto Yoneshima, Hideaki Mizutani, Tomohiro Ozaki, Satoru Kitazono, Naoki Ide, Keisuke Suzuki, Hidehito Horinouchi, Yuichiro Ohe
Journal: Annals of Oncology (2022)
O13-6 Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study
Authors: Toshio Shimizu, Satoru Kitazono, Edward B. Garon, Melissa L. Johnson, Aaron Lisberg, Alexander Spira, Noboru Yamamoto, Rebecca S. Heist, Jacob M. Sands, Funda Meric-Bernstam, Yoshitaka Zenke, Noriko Yanagitani, Jonathan Greenberg, Fumiaki Kobayashi, Yui Kawasaki, Kiyotaka Yoh
Journal: Annals of Oncology (2022)
O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup
Authors: Takayuki Yoshino, Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelius J.A. Punt, Denis Smith, Rocio Garcia-Carbonero, Peter Gibbs, T. Le Dung, Noriaki Adachi, David Fogelman, Patricia Marinello, Luis A. Diaz
Journal: Annals of Oncology (2022)
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors
Authors: Kentaro Yamazaki, Takayuki Yoshino, Kazunori Honda, Yasutoshi Kuboki, Takeshi Kawakami, Seiichiro Mitani, Yoshiaki Nakamura, Hiroya Taniguchi, Hideaki Bando, Tomoyuki Tanaka, Keisuke Tada, Nathalie Fagniez, Kei Muro
Journal: Annals of Oncology (2022)
MO6-5 Clinical relevance of adjuvant chemotherapy in patients who underwent surgery following neoadjuvant modified FOLFIRINOX
Authors: So Heun Lee, Changhoon Yoo, Sora Kang, Heung-Moon Chang, Jae Ho Jeong, Kyu-Pyo Kim, Baek-Yeol Ryoo
Journal: Annals of Oncology (2022)
MO2-3 Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer – Additional safety report of randomized Japanese phase 2 trial
Authors: Masafumi Ikeda, Tatsuya Ioka, Makoto Ueno, Takuji Okusaka, Zhaoyang Teng, Momoko Furuya, Junji Furuse
Journal: Annals of Oncology (2022)
O15-2 HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy
Authors: Tatsuya Yokoyama, Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Yoshito Komatsu
Journal: Annals of Oncology (2022)
P68-4 Feasibility study of a new tissue-based comprehensive genome profiling test
Authors: Masahiro Yoshioka, Masashi Kanai, Tomohiro Kondo, Keita Fukuyama, Yoshihiro Yamamoto, Koji Yamanoi, Nobuko Kawaguchi-Sakita, Motoo Nomura, Akira Yokoyama, Osamu Kikuchi, Junichi Matsubara, Atsushi Yamada, Yukiko Mori, Sachiko Minamiguchi, Takahiro Yamada, Shigemi Matsumoto, Manabu Muto
Journal: Annals of Oncology (2022)
Graphene oxide/gallium nanoderivative as a multifunctional modulator of osteoblastogenesis and osteoclastogenesis for the synergistic therapy of implant-related bone infection
Authors: Ying Yang, Min Li, Bixia Zhou, Xulei Jiang, Dou Zhang, Hang Luo
Journal: Bioactive Materials (2022)

Currently, implant-associated bacterial infections account for most hospital-acquired infections in patients suffering from bone fractures or defects. Poor osseointegration and aggravated osteolysis remain great challenges for the success of implants in infectious scenarios. Consequently, developing an effective surface modification strategy for implants is urgently needed. Here, a novel nanoplatform (GO/Ga) consisting of graphene oxide (GO) and gallium nanoparticles (GaNPs) was reported, followed by investigations of its in vitro antibacterial activity and potential bacterium inactivation mechanisms, cytocompatibility and regulatory actions on osteoblastogenesis and osteoclastogenesis. In addition, the possible molecular mechanisms underlying the regulatory effects of GO/Ga nanocomposites on osteoblast differentiation and osteoclast formation were clarified. Moreover, an in vivo infectious microenvironment was established in a rat model of implant-related femoral osteomyelitis to determine the therapeutic efficacy and biosafety of GO/Ga nanocomposites. Our results indicate that GO/Ga nanocomposites with excellent antibacterial potency have evident osteogenic potential and inhibitory effects on osteoclast differentiation by modulating the BMP/Smad, MAPK and NF-κB signaling pathways. The in vivo experiments revealed that the administration of GO/Ga nanocomposites significantly inhibited bone infections, reduced osteolysis, promoted osseointegration located in implant-bone interfaces, and resulted in satisfactory biocompatibility. In summary, this synergistic therapeutic system could accelerate the bone healing process in implant-associated infections and can significantly guide the future surface modification of implants used in bacteria-infected environments.